Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.57 |
| ▸ | DUSP4 | Q13115 | 1/20 | 0.57 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133570 | 0.81 | MAPT (0.66) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL14133112 | 0.80 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL14132635 | 0.75 | PTGES (0.67) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL14133550 | 0.74 | CDC25B (0.60) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL14133607 | 0.74 | KDM4E (0.84) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL12892076 | 0.74 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL7859595 | 0.73 | P2RX3 (0.65) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL14133405 | 0.73 | PTGS2 (0.64) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL14133212 | 0.72 | SIRT2 (0.54) | MEN1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL3392607 | 0.72 | CDC25B (0.73) | MEN1KMT2AMAPTHPGDPTP4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | MEN1 40/4885KMT2A 2063/4885SMN1; SMN2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.